Resistance is defined as progressive disease during therapy, with or without an initial response, or relapse within 6 months of completing therapy with an anthracycline-containing adjuvant regimen.
Indication is based on demonstration of a response rate.
No results from controlled trials demonstrating a clinical benefit resulting from treatment, such as improvement in disease-related symptoms, disease progression, or survival, are available. Swallow tablets with water. Carefully monitor patients for toxicity. Manage toxicity with symptomatic therapy, dose interruptions, and capecitabine dose adjustment. Once dose is decreased, it should not be increased later.